D
Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
Price:
188
IDR
0.53%
Market Closed
Market Cap:
235B
IDR
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
DGNS Alert
Diagnos Laboratorium Utama PT Tbk
188
+1 (+0.53%)
| 52 Week Range |
129
228
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
Delete Alert
This alert will be permanently deleted.
Income Statement
Earnings Waterfall
Diagnos Laboratorium Utama PT Tbk
Diagnos Laboratorium Utama PT Tbk
|
Revenue
|
281.3B
IDR
|
|
Cost of Revenue
|
-155.2B
IDR
|
|
Gross Profit
|
126.1B
IDR
|
|
Operating Expenses
|
-126.2B
IDR
|
|
Operating Income
|
-71.6m
IDR
|
|
Other Expenses
|
-1.8B
IDR
|
|
Net Income
|
-1.9B
IDR
|
Income Statement
Diagnos Laboratorium Utama PT Tbk
Diagnos Laboratorium Utama PT Tbk
Currency: IDR
| Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
882
|
0
|
0
|
0
|
|
| Revenue |
95 668
N/A
|
152 031
+59%
|
183 171
+20%
|
255 411
+39%
|
307 629
+20%
|
333 309
+8%
|
302 182
-9%
|
272 200
-10%
|
230 248
-15%
|
195 178
-15%
|
192 886
-1%
|
172 634
-10%
|
167 242
-3%
|
156 173
-7%
|
145 696
-7%
|
149 805
+3%
|
155 530
+4%
|
163 072
+5%
|
239 569
+47%
|
239 955
+0%
|
281 346
+17%
|
|
| Gross Profit | ||||||||||||||||||||||
| Cost of Revenue |
(56 531)
|
(82 763)
|
(96 461)
|
(130 553)
|
(148 471)
|
(164 062)
|
(151 681)
|
(136 331)
|
(122 904)
|
(105 470)
|
(97 881)
|
(92 405)
|
(92 112)
|
(89 315)
|
(85 899)
|
(86 768)
|
(88 233)
|
(90 238)
|
(134 295)
|
(133 781)
|
(155 212)
|
|
| Gross Profit |
39 137
N/A
|
69 268
+77%
|
86 710
+25%
|
124 859
+44%
|
159 158
+27%
|
169 247
+6%
|
150 500
-11%
|
135 868
-10%
|
107 344
-21%
|
89 708
-16%
|
95 006
+6%
|
80 229
-16%
|
75 129
-6%
|
66 857
-11%
|
59 797
-11%
|
63 037
+5%
|
67 297
+7%
|
72 834
+8%
|
105 274
+45%
|
106 175
+1%
|
126 135
+19%
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(15 664)
|
(20 575)
|
(19 735)
|
(32 052)
|
(43 569)
|
(52 799)
|
(67 221)
|
(69 623)
|
(70 471)
|
(76 165)
|
(77 672)
|
(77 296)
|
(78 634)
|
(76 125)
|
(73 370)
|
(72 956)
|
(73 022)
|
(70 910)
|
(106 107)
|
(107 088)
|
(126 206)
|
|
| Selling, General & Administrative |
(11 880)
|
(17 696)
|
(18 323)
|
(29 730)
|
(43 596)
|
(51 016)
|
(66 143)
|
(66 737)
|
(65 528)
|
(70 103)
|
(72 298)
|
(72 075)
|
(73 151)
|
(70 974)
|
(65 503)
|
(64 152)
|
(64 701)
|
(61 766)
|
(91 817)
|
(92 880)
|
(110 434)
|
|
| Research & Development |
(1 106)
|
0
|
(593)
|
(683)
|
0
|
0
|
(274)
|
(390)
|
(543)
|
(714)
|
(586)
|
0
|
(510)
|
(364)
|
(249)
|
(484)
|
(337)
|
(759)
|
(1 171)
|
(1 200)
|
(1 415)
|
|
| Depreciation & Amortization |
(877)
|
(1 009)
|
(808)
|
(1 125)
|
(1 177)
|
(2 199)
|
(2 857)
|
(4 002)
|
(5 249)
|
(6 032)
|
(6 683)
|
(7 237)
|
(7 500)
|
(7 633)
|
(8 154)
|
(8 161)
|
(8 337)
|
(8 349)
|
(12 524)
|
(12 485)
|
(14 145)
|
|
| Other Operating Expenses |
(1 801)
|
(1 870)
|
(11)
|
(515)
|
1 204
|
416
|
2 052
|
1 506
|
848
|
685
|
1 895
|
2 015
|
2 528
|
2 847
|
535
|
(159)
|
352
|
(36)
|
(596)
|
(522)
|
(212)
|
|
| Operating Income |
23 473
N/A
|
48 692
+107%
|
66 975
+38%
|
92 807
+39%
|
115 590
+25%
|
116 448
+1%
|
83 279
-28%
|
66 245
-20%
|
36 873
-44%
|
13 543
-63%
|
17 333
+28%
|
2 933
-83%
|
(3 504)
N/A
|
(9 267)
-164%
|
(13 573)
-46%
|
(9 919)
+27%
|
(5 725)
+42%
|
1 924
N/A
|
(833)
N/A
|
(914)
-10%
|
(72)
+92%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(774)
|
(176)
|
(350)
|
(527)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(286)
|
(21)
|
(1)
|
(1)
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
23 473
N/A
|
48 692
+107%
|
66 975
+38%
|
92 807
+39%
|
115 590
+25%
|
116 448
+1%
|
83 279
-28%
|
66 245
-20%
|
36 873
-44%
|
13 543
-63%
|
17 333
+28%
|
2 933
-83%
|
(3 504)
N/A
|
(9 267)
-164%
|
(13 573)
-46%
|
(9 919)
+27%
|
(5 725)
+42%
|
864
N/A
|
(1 030)
N/A
|
(1 265)
-23%
|
(600)
+53%
|
|
| Net Income | ||||||||||||||||||||||
| Tax Provision |
(5 998)
|
(11 669)
|
(14 289)
|
(19 889)
|
(25 012)
|
(27 535)
|
(18 975)
|
(15 336)
|
(8 233)
|
(1 055)
|
(4 669)
|
(2 134)
|
(1 997)
|
(878)
|
(83)
|
(53)
|
965
|
(116)
|
993
|
0
|
(1 303)
|
|
| Income from Continuing Operations |
17 475
|
37 023
|
52 687
|
72 918
|
90 578
|
88 913
|
64 304
|
50 909
|
28 639
|
12 488
|
12 665
|
799
|
(5 502)
|
(10 146)
|
(13 656)
|
(9 973)
|
(4 759)
|
747
|
(38)
|
(1 381)
|
(1 903)
|
|
| Net Income (Common) |
17 475
N/A
|
37 023
+112%
|
52 687
+42%
|
72 918
+38%
|
90 578
+24%
|
88 913
-2%
|
64 304
-28%
|
50 909
-21%
|
28 639
-44%
|
12 488
-56%
|
12 665
+1%
|
799
-94%
|
(5 502)
N/A
|
(10 146)
-84%
|
(13 656)
-35%
|
(9 973)
+27%
|
(4 759)
+52%
|
747
N/A
|
(38)
N/A
|
(1 381)
-3 552%
|
(1 903)
-38%
|
|
| EPS (Diluted) |
13.98
N/A
|
74.04
+430%
|
42.15
-43%
|
58.33
+38%
|
72.46
+24%
|
71.13
-2%
|
51.44
-28%
|
40.73
-21%
|
22.91
-44%
|
9.99
-56%
|
10.13
+1%
|
0.64
-94%
|
-4.4
N/A
|
-8.12
-85%
|
-10.92
-34%
|
-7.98
+27%
|
-3.81
+52%
|
0.6
N/A
|
-0.03
N/A
|
-1.11
-3 600%
|
-1.52
-37%
|
|
Switch to:
Switch to:
See Also
Discover More
